Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

Trial Profile

Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2017 Status changed from recruiting to completed.
    • 06 Dec 2016 Preliminary results (n=7) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top